– USA, MA – Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today it appointed Paul J. Sekhri to its Board of Directors. Mr. Sekhri is an accomplished industry executive, with more than 25 years of experience in life sciences strategy, corporate development and corporate finance, having served in senior leadership positions at several pharmaceutical companies, including Novartis, Teva and Sanofi. He is currently President and Chief Executive Officer of Lycera, and he also serves on its board of directors.
“Paul has significant experience in developing strategic relationships and corporate collaborations for biopharmaceutical companies through both management and board roles. We welcome his contributions to our Board and the guidance he provides our management team,” said Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral.
John J. Rydzewski, Executive Chairman of Enumeral, added, “Paul adds important biopharmaceutical industry experience to our team, and his successful track record of service as an independent director of public biotech companies will greatly benefit Enumeral in achieving our strategic and operational objectives on behalf of our shareholders.”
“I am delighted to join Enumeral’s board of directors and appreciate the opportunity to work with them in support of the company’s internal pipeline development and strategic partnering activities,” said Mr. Sekhri. “Enumeral is in a unique position to advance immunotherapy discovery and development, having assembled an exceptional management team and a platform to elucidate fundamental knowledge on how immunotherapies work in each patient.”
Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi, and before that, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries. Prior to this, Mr. Sekhri was Operating Partner and Head, Biotech Operations Group at TPG Biotech, where he was responsible for a portfolio of more than 50 life science firms. Previously, Mr. Sekhri was founder, President and Chief Executive Officer of Cerimon Pharmaceuticals, and before Cerimon, he was President and Chief Business Officer of Ariad Pharmaceuticals. He also held senior positions at Novartis, including Senior Vice President and Head, Global Search and Evaluation and M&A. Mr. Sekhri is also a director of Veeva Systems and has served as a director on numerous private and public company boards, including KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions and Tandem Diabetes, and as a board advisor to IMS Health. He serves on the Board of Trustees for the non-profit Cancer Research Institute and on the Industry Advisory Boards of the Michael J. Fox Foundation, the TB Alliance and the Tectonic Theatre Project. Mr. Sekhri received a B.S. from the University of Maryland and completed postgraduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine.
Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We believe we have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. We believe our unique capabilities enable us to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. We are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.